|Articles|May 1, 2001
Supplements and Featured Publications
- Artherosclerosis: Achieving Optimal Outcomes in Statin Therapy
- Volume 7
- Issue 5 Suppl
Surrogate Endpoints and Newer Risk Markers in Atherosclerosis Management
Author(s)Christie M. Ballantyne, MD
Advertisement
Articles in this issue
about 25 years ago
Participating Facultyabout 25 years ago
Introductionabout 25 years ago
Should All Patients with Cardiovascular Disease Receive Statin Therapy?about 25 years ago
Threshold Level or Not for Low-Density Lipoprotein Cholesterolabout 25 years ago
Statins--Differences and Similaritiesabout 25 years ago
What Do the Statin Trials Tell Us?about 25 years ago
New Therapies on the Horizonabout 25 years ago
A New Statin: A New StandardAdvertisement
Advertisement
Advertisement
Trending on AJMC
1
Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure
2
COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV
3
Real-World Data Show MASH Progresses Faster Than Trials Suggest
4
Sarcoma's Rarity Limits Trials and Biomarker-Driven Treatment Options: Alexander Spira, MD, PhD, FACP, FASCO
5